Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments: 2015-2019

Historic Long-Term Investments for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2019 value amounting to $19.0 million.

  • Lineage Cell Therapeutics' Long-Term Investments fell 6.40% to $19.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.0 million, marking a year-over-year decrease of 6.40%. This contributed to the annual value of $19.0 million for FY2019, which is 6.40% down from last year.
  • According to the latest figures from FY2019, Lineage Cell Therapeutics' Long-Term Investments is $19.0 million, which was down 6.40% from $20.3 million recorded in FY2018.
  • Lineage Cell Therapeutics' Long-Term Investments' 5-year high stood at $100.0 million during FY2016, with a 5-year trough of $4.7 million in FY2015.
  • For the 3-year period, Lineage Cell Therapeutics' Long-Term Investments averaged around $35.8 million, with its median value being $20.3 million (2018).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Long-Term Investments surged by 2,041.70% in 2016, and later tumbled by 70.25% in 2018.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Long-Term Investments stood at $4.7 million in 2015, then surged by 2,041.70% to $100.0 million in 2016, then tumbled by 31.79% to $68.2 million in 2017, then crashed by 70.25% to $20.3 million in 2018, then decreased by 6.40% to $19.0 million in 2019.